- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06448754
Étude de plateforme exploratoire de phase II sur les schémas d'amorçage Volrustomig (eVOLVE-01)
Une étude ouverte de phase II pour évaluer l'innocuité, la tolérabilité, la pharmacocinétique, l'immunogénicité et l'activité antitumorale des schémas d'amorçage Volrustomig en association avec d'autres agents anticancéreux chez les participants atteints de tumeurs solides (eVOLVE-01)
Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This Phase II, platform, open-label, multicenter study will evaluate the efficacy, safety, and tolerability of volrustomig in combination with anticancer drugs in various solid tumor types.
This platform study currently includes 2 substudies:
Substudy 1: metastatic non-small cell lung cancer (mNSCLC) (non-squamous [NSQ]). Participants will be randomized in two treatment arms: Arm 1A and Arm 1B.
Substudy 2: mNSCLC (squamous [SQ] or NSQ). Participants will enroll to the Arm 2A only.
All arms will test a volrustomig dosing in combination with chemotherapy.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
-
Beijing, Chine, 100730
- Research Site
-
Hangzhou, Chine, 310014
- Research Site
-
Jinan, Chine, 250013
- Research Site
-
Yantai, Chine, 264000
- Research Site
-
Zhengzhou, Chine, 450000
- Research Site
-
-
-
-
-
Seongnam, Corée du Sud, 13620
- Research Site
-
Seoul, Corée du Sud, 03722
- Research Site
-
Suwon, Corée du Sud, 16247
- Research Site
-
-
-
-
-
A Coruña, Espagne, 15009
- Research Site
-
Alcorcón, Espagne, 28922
- Research Site
-
Barcelona, Espagne, 08041
- Research Site
-
Madrid, Espagne, 28041
- Research Site
-
Málaga, Espagne, 29004
- Research Site
-
Pamplona, Espagne, 31008
- Research Site
-
Santander, Espagne, 39008
- Research Site
-
Santiago de Compostela, Espagne, 15706
- Research Site
-
Valencia, Espagne, 46026
- Research Site
-
Valencia, Espagne, 46015
- Research Site
-
-
-
-
-
Bois-Guillaume, France, 76031
- Research Site
-
Caen, France, 14076
- Research Site
-
Dijon, France, 21079
- Research Site
-
Montpellier, France, 34070
- Research Site
-
-
-
-
-
Athens, Grèce, 115 27
- Research Site
-
Athens, Grèce, 12462
- Research Site
-
Elaiones, Grèce, 546 23
- Research Site
-
Piraeus, Grèce, 185 47
- Research Site
-
Thessaloniki, Grèce, 57001
- Research Site
-
-
-
-
-
Batumi, Géorgie, 6010
- Research Site
-
Tbilisi, Géorgie, 0144
- Research Site
-
Tbilisi, Géorgie, 0112
- Research Site
-
Tbilisi, Géorgie, '0159
- Research Site
-
Tbilisi, Géorgie, 186
- Research Site
-
Tbilisi, Géorgie, 0114
- Research Site
-
-
-
-
-
Genoa, Italie, 16132
- Research Site
-
Meldola, Italie, 47014
- Research Site
-
Milan, Italie, 20133
- Research Site
-
Naples, Italie, 80131
- Research Site
-
Orbassano, Italie, 10043
- Research Site
-
Perugia, Italie, 06132
- Research Site
-
Rozzano, Italie, 20089
- Research Site
-
Udine, Italie, 33100
- Research Site
-
Verona, Italie, 37134
- Research Site
-
-
-
-
-
Lisbon, Le Portugal, 1649-035
- Research Site
-
Lisbon, Le Portugal, 1169-050
- Research Site
-
Lisbon, Le Portugal, 1400-038
- Research Site
-
Porto, Le Portugal, 4099-001
- Research Site
-
-
-
-
-
Kuala Lumpur, Malaisie, 59100
- Research Site
-
Kuching, Malaisie, 93586
- Research Site
-
Perai, Malaisie, 13700
- Research Site
-
-
-
-
-
Cluj-Napoca, Roumanie, 400641
- Research Site
-
Craiova, Roumanie, 200542
- Research Site
-
Floreşti, Roumanie, 407280
- Research Site
-
-
-
-
-
Belgrade, Serbie, 11000
- Research Site
-
-
-
-
-
Geneva, Suisse, 1205
- Research Site
-
Lausanne, Suisse, 1011
- Research Site
-
Winterthur, Suisse, 8401
- Research Site
-
Zurich, Suisse, 8091
- Research Site
-
-
-
-
-
Changhua, Taïwan, 50006
- Research Site
-
New Taipei City, Taïwan, 23561
- Research Site
-
Taipei, Taïwan, 106
- Research Site
-
Taipei, Taïwan, 110
- Research Site
-
-
-
-
California
-
Los Angeles, California, États-Unis, 90067
- Research Site
-
-
North Carolina
-
Chapel Hill, North Carolina, États-Unis, 27514
- Research Site
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Key Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with no deterioration.
- Life expectancy greater than or equal to (>=) 12 weeks.
- Adequate organ and bone marrow function.
- Body weight greater than (>) 35 kilograms (kg) at screening and at randomization.
- Histologically or cytologically documented NSQ NSCLC in substudy 1 and SQ or NSQ mNSCLC in substudy 2.
- Absence of sensitizing epidermal growth factor receptor (EGFR) mutations.
- Absence of documented tumor genomic alteration results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved targeted 1L therapies.
- At least one measurable lesion not previously irradiated that can be accurately measured at baseline as >= 10 millimeter (mm) in the longest diameter.
Key Exclusion Criteria:
- Spinal cord compression.
- History of primary active immunodeficiency.
- Active or prior documented autoimmune or inflammatory disorders.
- Mixed small-cell lung cancer and NSCLC histology or sarcomatoid variant.
- Brain metastases unless asymptomatic, stable, and not requiring steroids for at least 14 days prior to start of study intervention. A minimum of 2 weeks must have elapsed between the end of radiation therapy and study enrollment.
- Prior chemotherapy or any other systemic therapy for Stage IV NSCLC. Participants who have received prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for local disease are eligible, provided that progression has occurred greater (>) 12 months from end of last therapy.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Substudy 1: Arm 1A: Volrustomig dose regimen 1 + Carboplatin and Pemetrexed
Volrustomig priming dose followed by volrustomig dosing regimen 1 in combination with carboplatin and pemetrexed. |
Participants will receive volrustomig via intravenous (IV) infusion.
Autres noms:
Participants will receive carboplatin via IV infusion. Participants will receive pemetrexed via IV infusion. |
|
Expérimental: Substudy 1: Arm 1B: Volrustomig dose regimen 2 + Carboplatin and Pemetrexed
Volrustomig priming dose followed by volrustomig dosing regimen 2 in combination with carboplatin and pemetrexed. |
Participants will receive volrustomig via intravenous (IV) infusion.
Autres noms:
Participants will receive carboplatin via IV infusion. Participants will receive pemetrexed via IV infusion. |
|
Expérimental: Substudy 2: Arm 2A: Volrustomig dose regimen 2 +Ramucirumab + Carboplatin + Pemetrexed or Paclitaxel
Volrustomig priming dose followed by volrustomig dosing regimen 2 in combination with ramucirumab and histology-specific chemotherapy (carboplatin+ either pemetrexed or paclitaxel). |
Participants will receive volrustomig via intravenous (IV) infusion.
Autres noms:
Participants will receive carboplatin via IV infusion. Participants will receive pemetrexed via IV infusion. Participants will receive ramucirumab via IV infusion. Participants will receive paclitaxel via IV infusion. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Délai: From screening (Days -28 to Day -1) up to 2 year 10 months
|
The safety and tolerability of volrustomig in combination with other anticancer drugs in participants with specified solid tumors will be assessed. |
From screening (Days -28 to Day -1) up to 2 year 10 months
|
|
Confirmed Objective Response rate (ORR)
Délai: Up to 2 year 10 months
|
ORR is defined as the percentage of participants who have a confirmed complete response (CR) or confirmed partial response (PR), as per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1). |
Up to 2 year 10 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Disease Control Rate (DCR)
Délai: Up to 2 year 10 months
|
DCR is defined as the percentage of participants who have a CR or PR or who have stable disease (SD) after the date of randomization or first dose. |
Up to 2 year 10 months
|
|
Duration of Response (DOR)
Délai: Up to 2 year 10 months
|
DOR is defined as the time from the date of first documented response until the date of documented progression or death due to any cause (in the absence of progression). |
Up to 2 year 10 months
|
|
Progression Free Survival (PFS)
Délai: Up to 2 year 10 months
|
PFS is defined as the time from randomization or first dose until radiological progression or death due to any cause (in the absence of progression). |
Up to 2 year 10 months
|
|
Overall Survival (OS)
Délai: Up to 2 year 10 months
|
OS is defined as the time from randomization or first dose until the date of death due to any cause. |
Up to 2 year 10 months
|
|
Serum Concentration of Volrustomig
Délai: Up to 2 year 10 months
|
The serum concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Trough concentration (Ctrough)
Délai: Up to 2 year 10 months
|
The trough concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Maximum Observed Concentration (Cmax)
Délai: Up to 2 year 10 months
|
The serum concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Area Under the Curve (AUC)
Délai: Up to 2 year 10 months
|
The AUC concentrations of volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed. |
Up to 2 year 10 months
|
|
Number of Participants with Positive Antidrug Antibodies (ADAs)
Délai: Up to 2 year 10 months
|
The incidence of ADAs against volrustomig or other anticancer agents in serum will be assessed. |
Up to 2 year 10 months
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs par site
- Tumeurs
- Maladies des voies respiratoires
- Maladies pulmonaires
- Tumeurs des voies respiratoires
- Tumeurs thoraciques
- Tumeurs pulmonaires
- Carcinome bronchique
- Tumeurs bronchiques
- Carcinome pulmonaire non à petites cellules
- Acides aminés, peptides et protéines
- Protéines
- Produits chimiques organiques
- Composés hétérocycliques
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Hydrocarbures
- Cycloparaffines
- Hydrocarbures, alicyclique
- Hydrocarbures, cyclique
- Terpènes
- Anticorps, monoclonal, humanisé
- Anticorps, monoclonal
- Anticorps
- Immunoglobulines
- Immunoprotéines
- Protéines sanguines
- Globulines sériques
- Globulines
- Complexes de coordination
- Guanine
- Hypoxanthines
- Purinones
- Purines
- Glutamates
- Acides aminés, acides
- Acides aminés
- Acides aminés, dicarboxylique
- Taxes
- Cyclodécanes
- Diterpènes
- Pémétrexed
- Ramucirumab
- Carboplatine
- Paclitaxel
Autres numéros d'identification d'étude
- D798KC00001
- 2023-509482-20-00 (Identificateur de registre: CTIS)
- 2023 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Qualified researchers can request access to anonymized individual patient-leveldata from AstraZeneca group of companies sponsored clinical trials via therequest portal Vivli.org. All requests will be evaluated as per the AZ disclosurecommitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes",indicates that AZ are accepting requests for IPD, but this does not mean allrequests will be approved.
Délai de partage IPD
AstraZeneca will meet or exceed data availability as per the commitment smade to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment athttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Critères d'accès au partage IPD
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure researchenvironmentVivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .